Strategic Focus Late-stage specialty pharma in CNS edema with potential high-value partnerships and licensing opportunities around life-threatening brain edema conditions, including stroke and traumatic brain injury.

Clinical Momentum Recent Phase 2 and Phase 3 efficacy data for CIRARA (intravenous glyburide) from the GAMES-RP and CHARM studies presented at ISC 2025, signaling strong clinical validation and potential for expansion into related CNS edema indications.

Market Opportunity Large unmet need with significant patient populations across multiple critical care indications and brain tumor contexts, suggesting multiple entry points for hospital-based adoption and payer discussions.

Engagement Signals Active industry engagement evidenced by attendance at major conferences (International Stroke Conference) and visibility of trial results, creating opening for investigator-initiated studies and regional partnering.

Financial Position Startup scale with modest revenue and a focused fundraising profile (revenue 1–10M, funding 18M), indicating potential for strategic alliances, co-development, or sponsored trials to accelerate commercialization.